A Phase 1, Open-Label Study in Healthy Adult Participants to Assess the Pharmacokinetics of JNJ-64281802 Administered as Different Multiple Dose Regimens
Latest Information Update: 18 Apr 2023
At a glance
- Drugs Mosnodenvir (Primary)
- Indications Dengue
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
Most Recent Events
- 13 Apr 2023 Status changed from recruiting to completed.
- 14 Feb 2023 Planned primary completion date changed from 24 Dec 2022 to 14 Aug 2023.
- 27 Sep 2022 Planned End Date changed from 24 Dec 2022 to 14 Aug 2023.